New PET scan to monitor cancer immunotherapy response
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a special PET scan that tracks immune activity to see if it can help monitor how well immunotherapy is working in people with various cancers. It is for patients about to start immunotherapy for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a malignant tumor and are about to receive immunotherapy (alone or with other treatments).
- You have never had immunotherapy before.
- You have at least one tumor that can be measured on a scan.
- You are able to care for yourself (ECOG score of 0-2) and expected to live at least 6 months.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during and 6 months after the study.
- You do not have an autoimmune disease or a history of serious heart, liver, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to track how well your tumor responds to immunotherapy. It may help doctors see early on if the treatment is working for you.
This trial uses a special PET/CT scan (called 18F-grazy-02) to look at a protein in your body that may show how well your immune system is fighting the cancer. It is for people with non-small cell lung cancer or melanoma to help their doctors monitor the effects of immunotherapy.
This trial uses a special PET scan called 68Ga-grazytracer to see how well immunotherapy is working in people with stomach, colon, or other gastrointestinal cancers. The goal is to find out if this scan can help doctors track your response to treatment.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
This trial uses a special PET scan to see how immune cells (CD8 T cells) are working in your tumor before you start a PD-1 immunotherapy drug (nivolumab or cetrelimab). The goal is to find out if the scan can predict whether the immunotherapy will work for you.
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
Hear when a new Solid Tumors and Hematological Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.